You have read all your free articles, to continue reading subscribe to read the rest of this content.
Aztiq Pharma Partners, a private equity fund led by Róbert Wessman, announced in the beginning of July that it has completed a 100 million USD financing to purchase a newly issued share equity in Alvogen US. Morgan Stanley led the financing, which was subscribed by international institutional inAlready a subscriber…
Initial analysis from an international clinical trial has indicated that the investigational drugs didn’t slow memory loss, cognitive decline in rare, inherited Alzheimer’s. The clinical trial evaluating whether two investigational drugs can slow memory loss and cognitive decline in people inAlready a subscriber Login You have read all your free…
Straight after ASCO, BIO 2022 was back in person in San Diego, June 13-17. Some 15,000 delegates from around the world attended. The exhibition hall was packed with national and regional pavilions from every country with skin in the life science game (except, surprisingly and controversially, theAlready a subscriber Login…
Biogen and Eisai will seek U.S. approval for the Alzheimer’s treatment aducanumab, which works on a similar principal as BioArctic's BAN2401. Biogen and Eisai decided to end the two late-stage trials of aducanumab in March when a so-called “futility analysis” revealed the trials had little Already a subscriber Login You…
